IP Library Granted Patent US 10,603,373
Granted Patent B2
US 10,603,373 · App. 16/124,648 · Granted Mar 31, 2020

Targets of

Inventors: Simon Urwyler (Bern, CH); Markus Haake (Estenfeld, DE); Michael Rudolf (Ittigen, CH)
A61K39/1045A61K39/104C07K14/212C07K14/22C07K16/1217A61K2039/55555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,603,373
App. No.
16/124,648
Granted
Mar 31, 2020
Kind
B2
Abstract

The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Claims (5)

1. A method of producing an antibody protective against Acinetobacter baumannii , the method comprising:

introducing a polypeptide comprising the sequence of SEQ ID NO: 8 into a mammal along with an adjuvant; and,

isolating the protective antibody;

wherein the antibody binds to the motif FEDFN (SEQ ID NO.: 37) and induces an effector function towards Acinetobacter baumannii.

2. The method of claim 1 , wherein the antibody is polyclonal.

Assignments (1)
SECURITY INTEREST Recorded Jun 21, 2023
From: ARIDIS PHARMACEUTICALS, INC.; ARIDIS BIOPHARMACEUTICALS, LLC; ARIDIS PHARMACEUTICALS, C.V.
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 064020/0055 →
Priority Claims (1)
EP 11191320 · Nov 30, 2011 · regional
Continuity (3)
Continuation In Part 15427976 · Feb 8, 2017
Division 14362058
Related Publication 20190000955A1 · Jan 3, 2019